天风证券:维持翰森制药(03692.HK)“增持”评级 25年中报显示内生增长超预期

智通财经
Yesterday
【天风证券:维持翰森制药(03692.HK)“增持”评级 25年中报显示内生增长超预期】智通财经APP获悉,天风证券发布研报称,维持翰森制药(03692.HK)“增持”评级,考虑到公司2025年有多笔大额BD交易款项到账,将2025年的营业收入从137.41亿元上调至146.68亿元,预计2026年和2027年的营业收入分别为158.35亿元和177.79亿元;将2025年的归母净利润从47.46亿元上调至51.67亿元,预计2026-2027年归母净利润分别为53.25亿元和61.33亿元。2025H1公司总收入74.34亿元,归母净利润为31.35亿元。创新药产品收入为61.45亿元,在总收入中的占比提升至82.7%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10